Key Highlights
- FY2026 Revenue rose 10% to £87.5 million (14% at constant currency), with profit before tax up 35% to £5.4 million.
- ECOVAXXIN MS, ECO's first in-house-developed Vaccine , launched across the European Union on 2 July 2026.
- Gross Margin improved to 49% from 45%, and EPS rose 31% to 3.26p.
- North America revenue grew 22% and Latin America grew 15%, driven by robust Demand for antibiotic Aivlosin.
- Net cash stood at £25.4 million at year-end, with the board continuing to reinvest profits rather than pay a Dividend .
The LSE-listed veterinary group has delivered double-digit revenue growth and profit gains for the year to March 2026, while its first proprietary vaccine, ECOVAXXIN MS, goes on sale across Europe—a milestone two decades in the making.
ECO Animal Health Group (LSE:EAH), the LSE-quoted veterinary medicines specialist best known for its antibiotic Aivlosin, has closed its financial year with revenue and profit both moving firmly in the right direction. Results for the twelve months to 31 March 2026, published on 15 July, showed revenue up 10% and profit before tax up 35%, alongside the commercial launch of the company's first vaccine developed entirely in-house. For a Business that has spent years building a research pipeline beyond its single blockbuster drug, the combination marks a notable point in its history.
What Happened
ECO reported revenue of £87.5 million for the year, up from £79.6 million—a 10% increase, or 14% on a constant currency basis, reflecting the drag of a weaker dollar against sterling. Profit before tax rose to £5.4 million from £4.0 million, while adjusted EBITDA climbed to £8.5 million from £7.3 million. Earnings Per Share increased 31% to 3.26p.
Alongside the numbers came the headline strategic event: ECOVAXXIN MS, a vaccine against Mycoplasma synoviae infection in layer and breeder chickens, was launched across the European Union on 2 July 2026, with a launch event held in Madrid. It received EU Marketing authorisation on 22 December 2025, over a month ahead of schedule, following a positive EMA opinion in November 2025. Chief executive David Hallas called the authorisation "a key milestone for ECO, enabling the first commercial launch from our innovative R& Amp ;D portfolio." Chief commercial officer Andrew Buglass said the group has "strategic distribution agreements in place across the major poultry markets in the EU," reaching a layer-bird population of more than 220 million birds annually.
Why It Matters
For most of its listed life, ECO has been a one-product story: Aivlosin, an antibiotic for respiratory and enteric disease in pigs and poultry, has generated the bulk of group revenue for years. That concentration has made the shares sensitive to disease cycles, generic competition and regulatory shifts affecting a single molecule. ECOVAXXIN MS is the first tangible evidence that R&D spending, historically a drag on profitability, can produce products of its own. Vaccines also carry a different regulatory profile: less exposed to tightening restrictions on livestock antibiotic use in Europe, and potentially higher-margin once volumes scale. A successful launch, however modest at first, changes the narrative from "will the pipeline ever deliver" to "how fast can it be commercialised."
Latest Financial and Operational Performance
Growth was broad-based but uneven by region. North America revenue grew 22% (28% at constant currency) and Latin America grew 15% (21% constant currency), on robust Aivlosin demand in both. China and Japan revenue rose 5%, a partial recovery after unusually low disease incidence had depressed prior-year comparatives. South and South-East Asia revenue fell 7%, attributed to weakness in India. Gross margin improved to 49% from 45%, helped by pricing and cost-of-goods management flagged in the March trading update.
The interim results to 30 September 2025 had already shown the turnaround taking shape: half-year revenue of £39.4 million, up 19% (23% constant currency), with the group swinging to a net profit of £710,000 from a £1.76 million loss a year earlier, and adjusted EBITDA up to £3.0 million from £0.4 million.
The board has again chosen not to recommend a dividend, saying its strategy is "to reinvest its profits to support its R&D pipeline." Net cash stood at £25.4 million at year-end, broadly flat on £25.0 million a year earlier, with 61% held outside China.
Key Numbers
- FY2026 revenue: £87.5 million, up 10% (14% constant currency) from £79.6 million
- Profit before tax: £5.4 million, up 35% from £4.0 million
- Adjusted EBITDA: £8.5 million, up 16% from £7.3 million
- Gross margin: 49%, up from 45%
- EPS: 3.26p, up 31% from 2.49p
- Net cash: £25.4 million (61% held outside China)
- North America revenue growth: 22% (28% constant currency)
- H1 FY2026 revenue: £39.4 million, up 19%
Growth Opportunities
ECOVAXXIN MS is registration-pending in the United States, Latin America and Asian markets beyond its EU launch, giving management further catalysts over the next two to three years. The company has also flagged ECOVAXXIN MG, which received a favourable safety assessment from the US Department of Agriculture in March 2026. Management has talked of up to nine pipeline products securing approvals within five to six years, across poultry and swine, though that should be treated as a medium-term ambition rather than a near-term certainty. Aivlosin itself continues to find growth in newer markets, with North America and Latin America the standout performers this year.
Risks Investors Should Know
ECO remains heavily dependent on Aivlosin for most of its revenue, and any regulatory tightening on antibiotic use in livestock, particularly in Europe, could pressure sales. The China and South-East Asia markets have proved volatile, swinging between unusually low disease incidence and stronger recovery periods, making forecasting difficult. Currency movements have already weighed on reported growth this year, with constant-currency growth of 14% well above the 10% reported figure. Newly launched vaccines typically ramp slowly, and ECOVAXXIN MS's initial contribution, the company noted only that "first orders" had been received, gives no indication yet of the pace of uptake. The absence of a dividend means returns depend entirely on reinvestment paying off.
What to Watch Next
Investors should watch early sales trends for ECOVAXXIN MS in EU markets, progress on its US and other international registrations, and further pipeline newsflow, including ECOVAXXIN MG. The next trading update, and margin progression against guidance for FY2027 profitability in line with market expectations, will mark whether momentum can be sustained.
Outlook
ECO Animal Health has delivered a year of genuine progress: double-digit revenue growth, materially higher profit, and the commercial debut of a vaccine built from its own research. The company remains a smaller, single-product-dependent business by sector standards, and the true test of its pipeline strategy will be measured over several years of vaccine sales rather than one launch event. But for a group that has long promised Diversification beyond Aivlosin, 2026 is the year that promise started to show up in the announcements, if not yet decisively in the numbers.






Please wait processing your request...